Zymeworks Inc. (ZYME)
Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma
Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cash-flow platform anchored by Yupelri. ZYME gains durable, growing cash flows—$60M annually from Yupelri—with patent protection to 2039, supporting internal R&D and reducing reliance on equity issuance. The acquisition's innovative financing structure ringfences risk, offers immediate accretion, and diversifies revenue beyond oncology, enhancing earnings visibility.
Theravance Stock Down 3% After Zymeworks Announces Buyout
TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine program.
Zymeworks Inc. (ZYME) M&A Call Transcript
Zymeworks Inc. (ZYME) M&A Call Transcript
Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality
Zymeworks is transitioning into an oncology royalty platform with a robust internal discovery engine, offering a differentiated risk-reward profile versus traditional biotech peers. ZYME's balance sheet is fortified with over $400 million in liquid assets, a $440 million milestone pipeline, and a $125 million share repurchase program, supporting operations beyond 2028. Zanidatamab's Priority Review for first-line HER2-positive GEA, with a PDUFA date of August 25, 2026, could trigger $265 million in near-term milestone payments and unlock substantial royalty streams.
Zymeworks Q1 Earnings Call Highlights
Zymeworks NASDAQ: ZYME reported a wider first-quarter loss as revenue declined from year-earlier milestone payments, while management highlighted regulatory catalysts for zanidatamab, progress across its antibody-drug conjugate pipeline and continued share repurchases.
Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript
Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.3 per share a year ago.
Zymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar Ziihera
Zymeworks (NASDAQ: ZYME) used a presentation at the Bloom Burton conference to outline how the company is repositioning itself around its first approved product and a growing stream of royalty and milestone revenue, while continuing to invest in internal research and development across antibody-drug conjugates (ADCs) and multispecific antibodies. The speaker, who noted it was the
Zymeworks Inc. (NASDAQ:ZYME) Receives Consensus Rating of “Moderate Buy” from Analysts
Shares of Zymeworks Inc. (NASDAQ: ZYME - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the thirteen ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, nine have assigned a buy recommendation and
Zymeworks FY25 Review: From Milestone Volatility To 2026 Upside
Zymeworks Inc. (ZYME) reported weak Q4 results, highlighting the volatility of its milestone-driven revenue model and underscoring execution risk ahead of commercialization. Despite top-line misses, ZYME improved FY25 profitability, narrowed net loss by 34%, and maintained strong liquidity with $270.6 million in cash and equivalents. The $250 million royalty-backed financing with Royalty Pharma extends ZYME's cash runway beyond 2028, reducing dilution risk but increasing dependence on Ziihera's commercial success.
Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript
Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript
Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.31 per share a year ago.
